Clin Osteol 2013; 18(3): 68-76

Osteonecrosis of the jaw in patients receiving antiresorptive therapy of osteoporosisOriginal contributions

J. Rosa, G. Pavíková, V. Palička

Osteonecrosis of the jaw (ONJ) is a known complication of high-dose antiresorptive therapy (AR) for bone malignancies, and is rarely (incidence rates of 1/10,000 and < 1/100,000 patient-years) seen also in patients receiving AR for osteoporosis. ONJ, defined as expo­ sure of thejaw bone lasting for more than 8 weeks, causes many complications. ONJ is frequently associated with an intervention in the oral cavity, which either accelerates its progression or is needed due to already existing ONJ. The dominant pathogenetic factor is likely to be decreased bone remodeling in the jaw bone tissue with physiologically high bone turnover, leading to changes in charac­ teristics of the alveolus and inhibiting the full range of physiological recovery mechanisms. Classification of ONJ has been elaborated and diagnostic methods are being improved. By strictly following simple preventive measures, this rare but ser for osteoporosis may become less frequent.

Keywords: osteonecrosis ofthejaw, osteoporosis, bisphosphonates, denosumab

Published: December 11, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosa J, Pavíková G, Palička V. Osteonecrosis of the jaw in patients receiving antiresorptive therapy of osteoporosis. Osteologický bulletin. 2013;18(3):68-76.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of jaw: report of a task force ofthe American Society for Bone andMineral Research. J Bone Miner Res 2007;22:1479-1491. Go to original source...
    2. Otto S, Abu-Id MH, Fedele S et al. Osteoporosis and bisphosphonates-related teonecrosis of the jaw: Not just a sporadic coincidence - a multi-centre study. J Cran Maxillofac Surg 2011;39:272-277. Go to original source...
    3. Goytia RN, Salama A, Khanuja HS. Bisphosphonates and osteonecrosis: poten treatment or serious complication? Orthopedic Clinics of North America 2009; 40:223-234. Go to original source...
    4. Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. J Oral Maxillofac Surgery 2011;40:277-284. Go to original source...
    5. Marx RE. ^midronate (Aredia) and zoledronate (Zometa) induced avascular ne­ crosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117. Go to original source...
    6. http://en.wikipedia.org/wiki/Phossy_jaw
    7. Marx RE. Uncovering the cause of "Phossy jaw" circa 1858 to 1906: oral and ma­ xillofacial surgery closed case files - case closed. J Oral Maxillofac Surgery 20 66:2356-2363. Go to original source...
    8. http://www.dentistryiq.com/articles/rdh/2009/06/the-return-of-the-dreaded-phossy-jaw.html
    9. Abu-Id M H, Warnke PH, Gottschalk J et al. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Cranio-maxillofac Surg 2008;36:95-103. Go to original source...
    10. Campisi G, Compilato D, Angelo I, Lo Muzio L, Colella G. Spontaneous bisp­ hosphonate-related osteonecrosis of the left hemi-mandible: similarities with phossy jaw. Indian J Dent Res 2012;23:683-685. Go to original source...
    11. Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone 2011; 49:42 49. Go to original source...
    12. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011;49:34-41. Go to original source...
    13. Ebetino FH, Hogan AM, Sun S et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011;49:20-33. Go to original source...
    14. Bone HG, Hosking D, Devogelaer J-P et al. Ten years' experience with alendro­ nate for osteoporosis in postmenopausal women. N Engl J Med 2004;350: 1189-1199. Go to original source...
    15. Black DM, Reid IR, Boonen S et al. The effect of 3 versus 6 years of zoledro acid treatment of osteoporosis: arandomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Mineral Res 2012;27:243-254. Go to original source...
    16. Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postme­ nopausal women. J Bone Miner Res 2004;19:1059-1066. Go to original source...
    17. Brown JP, Prince RL, Deal C et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopau­ sal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153-161. Go to original source...
    18. Khosla S, Bilezikian JP, Dempster DW et al. Benefits and Risks of Bisphosphonate Therapy for Osteoporosis. J Clin Endocrinol Metab 2012;97: 2272-2282. Go to original source...
    19. Bone HG, Bolognese MA, Yuen KC et al. Effects of denosumab treatment and d continuation on bone mineral density and bone turnover markers in postmenopau­ sal women with low bone mass. J Clin Endocrinol Metab 2011;96:972-980. Go to original source...
    20. Devold HM, Doung GM, Tverdal A et al. Prescription of anti-osteoporosis dr during 2004-2007 - a nationwide register study in Norway. Eur J Clin Pharmacol 2010;66:299-306. Go to original source...
    21. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bis­ phosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65: 369-376.
    22. Ruggiero SL, Dodson TB, Assael LA et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis the jaws - 2009 update. J Oral Maxillofac Surg 2009;67:2-12. Go to original source...
    23. Bedogni A, Fusco V, Agrillo A, Campisi G et al. Learning from experience. Proposal of a redefined definition and staging system for bisph osteonecrosis f the jaw (BRONJ). Oral Diseases 2012;18:621-623. Go to original source...
    24. Grbic JT, Landesberg R, Lin SO et al. Incidence of osteonecrosis ofthe jaw in men with postmenopausal osteoporosis in the health outcomes and reduced inci­ dence with zoledronic acid once yeary pivotal fracture trial. J Am Dent Assoc 2008;139:32 40. Go to original source...
    25. Mavrokokki T, Cheng A, Stein B, Goss A Nature and frequency of bisphospho­ nate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423. Go to original source...
    26. Felsenberg D, Hoffmeister B, Amling M, Mundlos S, Fratzl P. Onkologie: Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Arztebl 2006; 103:3078-3081.
    27. Rachner TD, Platzbecker U, Felsenberg D, Hofbauer LC. Osteonecrosis ofthe jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin Proc 2013;88:418^19. Go to original source...
    28. Brooks JK, Gilson AJ, Sindler AJ et al. Osteonecrosis of the jaws assoc use of risedronate: report of two cases. Oral Surg Oral Med Oral Pthol Oral Radiol Endod 2007;103:780-786. Go to original source...
    29. Compston J. Pthofysiology of atypi jaw. Osteoporos Int 2011;22:2951-2961. Go to original source...
    30. Lo JC, O'Ryan FS, Gordon NP et al. Prevalence of osteonecrosis of the jaw in tients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68: 243-253. Go to original source...
    31. Khan AA, Rios LP, Sándor GK et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 2011;38:1396-1402. Go to original source...
    32. Diel IJ, Fogelman I, Al-Nawas B et al. Pthophysiology, risk factors and ma ment of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Critical Reviews in Oncology/Hematology 2007;64:198-207. Go to original source...
    33. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for tre­ atment of bonemetastases in men with castration-resis domised, double-blind study. Lancet 2011;377:813-822. Go to original source...
    34. Papapoulos S, Chapurlat R, Libanati C et al. Five years of denosumab exposu women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012;27:694-701. Go to original source...
    35. Lippuner K, Roux C, Bone HG et al. Denosumab Treatment of Postmenopausal Women With Osteoporosis for 7 Years: Clinical Fracture Results From the First 4 Years of the FREEDOM Extension. Předneseno na ESCEO-IOF; Řím, 18. 4. 2013.
    36. Allen MR, Burr DB. The pathogenesis of bisphosphonate related osteone the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67 (5 Suppl):61-70. Go to original source...
    37. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate- induced osteonecrosis: factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-2410. Go to original source...
    38. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Osteonecro of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-4038. Go to original source...
    39. Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bispho­ sphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061. Go to original source...
    40. Bedogni A, Blandamura S, Lokmic Z et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:358-364. Go to original source...
    41. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of thejaws in patients treated with bisphosphonates:histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-160. Go to original source...
    42. Kobayashi Y, Hiraga T, Ueda A et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration and promotes pro feration and adhesion tohydroxyapatite of oral bacteria, with causing no osteone­ crosis of the jaw in mice. J Bone Miner Metab 2010;28:165-175. Go to original source...
    43. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-assoc jaw caused by soft tissue toxicity? Bone 2007;41:318-320. Go to original source...
    44. Landesberg R, Cozin M, Cremers S et al. Inhibition of oral muco healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839-847. Go to original source...
    45. Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone 2009;44:4-10. Go to original source...
    46. Kos M, Luczak K. Bisphosphonates promote jaw osteonecrosis through facili ting bacterial colonisation. Bioscience Hypotheses 2009;2:34-36. Go to original source...
    47. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors on, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575. Go to original source...
    48. Palomo L, Bissada N, Liu J. Bisphosphonate therapy for bone loss in patients with osteoporosis and periodontal disease: cli rature. Quintessence Int 2006;37:103-107.
    49. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple m ma patients. Clinical features and risk factors. J Clin Oncol 2006;24:945-952. Go to original source...
    50. Khamaisi M, Regev E, Yarom N et al. Possible association between diabetes bisphosphonate - related jaw osteonecrosis. J Clin Endocrinol Metab 2007; 92: 1172-1175. Go to original source...
    51. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillo Surg 2008;66:625-631. Go to original source...
    52. Otto S, Baumann S, Ehrenfeld M, Pautke C. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluores­ cence guided bone resection. J Craniomaxillofac Surg 2013; článek v tisku, dostupný online od 4. 7. 2013 na aip/10105182. http://www.sciencedirect.com/science/journal/ Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.